𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response

✍ Scribed by Yago González-Lama; Antonio López-San Román; Ignacio Marín-Jiménez; Begoña Casis; Isabel Vera; Fernando Bermejo; José Lázaro Pérez-Calle; Carlos Taxonera; Francisca Martínez-Silva; Luis Menchén; Pilar Martínez-Montiel; Marta Calvo; José Antonio Carneros; Pilar López; Juan Luis Mendoza; José María Milicua; Alaín Huerta; Fernando Sánchez; Luis Abreu; Natalia López-Palacios; José Maté; Javier P. Gisberta

Book ID
119891991
Publisher
Elsevier Science
Year
2008
Tongue
Spanish
Weight
98 KB
Volume
31
Category
Article
ISSN
0210-5705

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of infliximab in pediatric Croh
Efficacy of infliximab in pediatric Crohn's disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy
✍ Frank M. Ruemmele; Alain Lachaux; Jean-Pierre Cézard; Alain Morali; Chantal Maur 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

## Background: Infliximab (ifx) is efficacious in inducing remission in severe forms of pediatric crohn's disease (cd). adult studies indicate that ifx is also safe and well tolerated as maintenance therapy. the present study aimed to evaluate in a prospective manner the efficacy and safety of ifx